The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2026 | Advice for community oncologists on managing patients with HL: when to refer to a specialist center
Cathy Burton, MB BChir, MD, MRCP, FRCPath, St James’s University Hospital, Leeds, UK, provides advice for community oncologists managing patients with relapsed Hodgkin lymphoma (HL). Dr Burton highlights the need for community practitioners to discuss treatment options with specialist centers, particularly for elderly patients and those being considered for transplant or clinical trials, to ensure optimal care and guidance on management. This interview took place at the 31st Congress of the European Hematology Association (EHA) in Stockholm, Sweden.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
You have to think about the broad range of patients that present with Hodgkin’s lymphoma and there are a huge number of patients really that fall into the teenage and young adult setting. I think they do benefit from being treated in a TYA center, and I would recommend to community practitioners to at least discuss treatment options with a TYA center and even suggest that they are treated at the center because I think they can get additional support from that...
You have to think about the broad range of patients that present with Hodgkin’s lymphoma and there are a huge number of patients really that fall into the teenage and young adult setting. I think they do benefit from being treated in a TYA center, and I would recommend to community practitioners to at least discuss treatment options with a TYA center and even suggest that they are treated at the center because I think they can get additional support from that. I think otherwise, in terms of being aware of the current first-line settings and the optimal treatment, especially for elderly patients, I think there can be some discussion about what’s the most appropriate treatment, what patients may tolerate. I think in terms of the relapse setting, obviously, if patients are being considered for transplant, then they should be discussed with a tertiary referral center. But I think as well, clinical trials are really important. I think particularly in the elderly setting as well, as I say, we have the RATIFY trial that’s for patients over 60. So I think actually considering what other treatment options are available for patients, particularly clinical trials, discussing that with an expert centre and then having some guidance in terms of how to manage their patients, I think is really important because I think Hodgkin’s lymphoma isn’t that common and actually for community physicians they may not see cases that often and actually I think it’s worth discussing with an expert centre just to guide treatment.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
